P-090: IS A DEDICATED MARKETING APPROVAL OF HYDROXYUREA IN SICKLE CELL DISEASE MAY INCREASE THE CLINICAL BENEFIT OF THE DRUG?

por F., GALACTÉROS, E., VOSKARIDOU, A., HABIBI, G., CANNAS, L., JOSEPH, G., LOKO, M., DE MONTALEMBERT
Publicado 2022

P-042: POPULATION PHARMACOKINETICS AND PHARMACODYNAMICS ANALYSIS OF HYDROXYUREA, IN ADULT PATIENTS WITH SICKLE CELL DISEASE (SCD) RECEIVING BOTH TABLETS OR CAPSULES FORMULATIONS, A...

por P., BARTOLUCCI, S., LEZZAR, A., HABIBI, G., DE LUNA, A., JEBALI, S., MARTINO, C., NOIZAT, C., FAUROUX, F., GALACTÉROS
Publicado 2022